Skip to main content
Figure 5 | BMC Psychiatry

Figure 5

From: Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study

Figure 5

Number of Discontinuation Emergent Signs and Symptoms reported by completers stopping treatment with escitalopram (n = 20). The number of new symptoms reported by the 20 patients who completed the study and tapered down the dose of escitalopram at 32 weeks prior to stopping treatment, as assessed using the Discontinuation Emergent Signs and Symptoms (DESS) scale scores.

Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us